In our work, we demonstrated the ability of both the target protein moiety and modified nanocarriers to bind ECs in vitro followed by the efficient, selective delivery of nanocarrier-coated MSCs in vivo to atherosclerotic lesions in the aorta, thereby reducing indiscriminate migration to other organs in the ApoE−/− mouse model of atherosclerosis. This evidence concerns the gene APOE and atherosclerosis.